2025
- Application submitted to the U.S. FDA for the second Phase III clinical trial of BRM421.
- On September 1, 2025, the Board of Directors approved an investment in Compass Bioinformatics Co., Ltd., marking the company’s entry into the fields of precision medicine and AI-based healthcare.
- The Phase I/IIb clinical trial (IND) of BRM411 for the treatment of glaucoma has received the Ministry of Health and Welfare’s conditional approval to proceed.
- The Phase II dose-finding, safety, and efficacy clinical trial (IND) of BRM421 for the treatment of dry eye disease has also received the Ministry of Health and Welfare’s conditional approval to proceed.
2024
- Approved by the Taiwan Stock Exchange Corporation for listing on December 16, 2024 (Stock Code: 6885).
- Completed a pre-IPO cash capital increase, raising NT$499.884 million.
- BRM421 received the 2024 International Innovation Award (IIA) from the Enterprise Asia organization.
- Acquired from Metagone Biotech ,Inc the original exclusive licenses from ITRI for two drug candidates and technologies targeting glaucoma and wet age-related macular degeneration (AMD).
- Completed the U.S. FDA application for Phase II clinical trial protocol amendment of BRM424 and initiated patient enrollment.
- Established operations in the National Biotechnology Research Park shared laboratories.
2023
- Completed the first Phase III clinical trial of BRM421 under the U.S. FDA.
- Received notification from the Taiwan Stock Exchange confirming that the Ministry of Economic Affairs Industrial Development Administration issued an official opinion recognizing the company as a “technology enterprise with market potential.”
- Completed the Series F cash capital increase, raising NT$1.4625 billion (approximately USD 48 million).
- Completed and obtained U.S. FDA approval to proceed with the Phase II clinical trial of BRM424.
2022
- Obtained U.S. FDA Orphan Drug Designation for BRM424
- Initiated the first Phase III clinical trial of BRM421 under the U.S. FDA.
- Completed the Series E cash capital increase, raising NT$600 million (approximately USD 20 million).
- Completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for BRM421.
- Received approval from the Taipei Exchange (TPEx) for the company’s initial public offering (IPO), with shares commencing trading on the Emerging Stock Board on June 23, 2022.
2021
- Completed the Series D cash capital increase, raising approximately NT$301 million (USD 11 million).
- Submitted an Orphan Drug Designation application for BRM424 to the U.S. FDA.
- Completed the Type C meeting with the U.S. FDA for BRM421.
2020
- Received the “2020 Potential Benchmark Award” from the Taiwan Bioindustry Development Association (TBA).
- Received the Gold Award for Innovative Technology at the Taipei Bio Awards.
- Completed the Phase II/III clinical trials of BRM421 under the U.S. FDA.
2019
- Completed formulation optimization of BRM421 and submitted the Phase II/III clinical trial application to the U.S. FDA.
- Received the Taipei City Spotlight Enterprise Investment Role Model Award.
- Received the 16th National Innovation Award.
- Signed a regional exclusive licensing agreement with Grand Pharmaceutical Group Limited, granting rights to develop and commercialize BRM421 for dry eye disease in China, Hong Kong, and Macau.
2018
- Completed the Series C cash capital increase, raising NT$185 million (USD 6 million).
- Presented Phase II clinical data of BRM421 at the American Academy of Ophthalmology (AAO) Annual Meeting.
- Established the spin-off startup “Ascendo Biotechnology, Inc.” in the Cayman Islands (Ascendo Biotechnology, Inc.).
- Received the Silver Award in the Pharmaceutical Category of the National Drug Technology Research and Development Awards.
- Completed the licensing and introduction of BRM141 and BRM25X into the company’s incubation program.
2017
- Completed the IND application for BRM132 with the U.S. FDA and obtained approval.
- Completed the first Phase II clinical trial of BRM421 under the U.S. FDA.
2016
- Signed early-stage incubation collaboration agreements for BRM141 and BRM25X with Mackay Memorial Hospital and National Cheng Kung University, respectively.
- Completed preclinical process development for BRM421 and submitted the IND application to the U.S. FDA.
- Approved by the Industrial Development Bureau of the Ministry of Economic Affairs as a biotech new drug company.
2015
- BRIM Biotech relocated its office to the Neihu Science Park in Taipei.
- Completed the Series B cash capital increase, raising USD 26 million.
- Signed a collaboration and development agreement for a new dengue fever drug with Janssen Pharmaceuticals, a Johnson & Johnson company.
- Acquired and licensed the peptide drug technology platform (PDSP) from Mackay Memorial Hospital.
2014
- Acquired and licensed the blood cancer drug BRM132 from a U.S. biotechnology company.
- Completed the Series A cash capital increase, raising USD 4 million
2013
- BRIM Biotechnology company has been established
